胆囊癌治疗中免疫疗法的最新进展

Update on immunotherapy in the management of gallbladder cancer.

作者信息

Kassab Joseph, Saba Ludovic, Gebrael Georges, Kais Sami, Kassab Rebecca, Kourie Hampig R

机构信息

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon.

出版信息

Immunotherapy. 2023 Jan;15(1):35-42. doi: 10.2217/imt-2022-0191. Epub 2023 Jan 9.

DOI:10.2217/imt-2022-0191

PMID:36617963

Abstract

Gallbladder cancer (GBC) is a relatively infrequent but highly lethal cancer with a poor prognosis. Management remains challenging and controversial, and most patients are diagnosed at an advanced stage. However, with the progressive advances in the use of immunotherapies, new treatment modalities are being implemented. In September 2022, the US FDA approved durvalumab (a PD-L1 inhibitor) in combination with chemotherapy for adult patients with locally advanced or metastatic GBC. This groundbreaking news is the first FDA approval for the use of immunotherapy in biliary tract cancers. This article reviews the newest advances and trials regarding immunotherapy for GBC.

摘要

胆囊癌（GBC）是一种相对罕见但致死率很高、预后较差的癌症。其治疗仍然具有挑战性且存在争议，大多数患者在晚期才被诊断出来。然而，随着免疫疗法应用的不断进步，新的治疗方式正在得以实施。2022年9月，美国食品药品监督管理局（FDA）批准度伐利尤单抗（一种程序性死亡受体配体1（PD-L1）抑制剂）与化疗联合用于治疗局部晚期或转移性GBC的成年患者。这一开创性的消息是FDA首次批准在胆道癌中使用免疫疗法。本文综述了关于胆囊癌免疫疗法的最新进展和试验。